Search Prime Grants

HT94252310382

Project Grant

Overview

Grant Description
Development and validation of innate immunome-targeted therapy to create prosurvival and organ-protective phenotype after hemorrhage at the point of injury.
Awardee
The Geneva Foundation
Grant Program (CFDA)
12.420 - Military Medical Research and Development
Awarding / Funding Agency
Defense Health Agency (DHA) [DoD]
Place of Performance
Tacoma, Washington 984024437 United States
Geographic Scope
Single Zip Code
Related Opportunity
W81XWH22PRMRPTTDA
The Geneva Foundation was awarded Innate Immunome-Targeted Therapy for Hemorrhage Survival Project Grant HT94252310382 worth $4,676,544 from Defense Health Agency in July 2023 with work to be completed primarily in Tacoma Washington United States. The grant has a duration of 4 years and was awarded through assistance program 12.420 Military Medical Research and Development.

Status
(Ongoing)

Last Modified 5/10/23

Period of Performance
7/1/23
Start Date
6/30/27
End Date
60.0% Complete

Funding Split
$4.7M
Federal Obligation
$0.0
Non-Federal Obligation
$4.7M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to HT94252310382

Additional Detail

Award ID FAIN
HT94252310382
SAI Number
None
Award ID URI
None
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Other
Awarding Office
HT9425 ARMY MED RES ACQ ACTIVITY
Funding Office
HT0989 CONG DIR MED RES PRGM / CDMRP - MM
Awardee UEI
TR9RX33188T4
Awardee CAGE
1D2D1
Performance District
06
Senators
Maria Cantwell
Patty Murray
Representative
Derek Kilmer

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
Defense Health Program, Defense (097-0130) Department of Defense-Military Grants, subsidies, and contributions (41.0) $4,676,544 100%
Modified: 5/10/23